Savara (NASDAQ:SVRA) Receives Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.

Separately, Piper Sandler raised their target price on shares of Savara from $7.00 to $16.00 and gave the stock an overweight rating in a research note on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara has an average rating of Buy and a consensus target price of $8.20.

Savara Stock Performance

Shares of NASDAQ:SVRA opened at $4.95 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 15.66 and a quick ratio of 15.66. Savara has a 1 year low of $1.83 and a 1 year high of $5.70. The firm has a market capitalization of $683.99 million, a PE ratio of -15.00 and a beta of 0.73. The business’s 50 day moving average price is $4.90 and its 200-day moving average price is $4.50.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, equities research analysts expect that Savara will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of Savara

Institutional investors have recently made changes to their positions in the company. Jennison Associates LLC increased its stake in Savara by 0.3% during the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after buying an additional 1,874,000 shares during the period. Vanguard Group Inc. lifted its position in Savara by 15.9% in the third quarter. Vanguard Group Inc. now owns 5,764,601 shares of the company’s stock valued at $21,790,000 after buying an additional 789,249 shares during the last quarter. Vivo Capital LLC boosted its stake in Savara by 9.1% during the fourth quarter. Vivo Capital LLC now owns 2,088,323 shares of the company’s stock worth $9,815,000 after buying an additional 174,974 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Savara during the fourth quarter valued at about $9,683,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.